Skip to main content
. 2019 Dec 4;69(8):1492–1501. doi: 10.1136/gutjnl-2019-318934

Figure 3.

Figure 3

Forest plot of PFS in subgroups of patients treated with TACE plus sorafenib and TACE alone. PFS, progression-free survival; TACE, transarterial chemoembolisation.